TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02297464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs - 2 per day for breakfast
Description: 11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 packet of oatmeal per day
Description: 11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 packet of oatmeal per day
Description: 11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
Study: NCT01737398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inotersen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT00789672

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: patching
Description: 2 hours daily patching

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: patching
Description: 2 hours daily patching

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa/carbidopa
Description: Oral levodopa 0.51mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation)
Study: NCT04473664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Single oral dose, 30 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Single oral dose, 30 mg tablet
Study: NCT00818428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Articulation Parent Group
Description: Parents are taught to carry out home practice activities that focus on the child's ability to correctly articulate target speech sounds and word shapes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialogic Reading Parent Group
Description: Parents are taught to read to their children using interactive techniques that help their children acquire new vocabulary, verbal reasoning abilities, and preliteracy skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialogic Reading Parent Group
Description: Parents are taught to read to their children using interactive techniques that help their children acquire new vocabulary, verbal reasoning abilities, and preliteracy skills.
Study: NCT01068769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: Taken orally, once a day in the morning for 3 weeks followed by a one week rest period
Study: NCT04965662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 300 mg, TWO tablets once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Truvada one tablet once daily
Study: NCT01840566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study: NCT05652452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamics
Description: Subjects in the neurodynamic group performed the 'Seated Straight Leg Slider' (SSLS) (Fig.1). To execute this sliding technique, subjects assumed a seated slump position (thoracic and lumbar flexion) which they needed to maintain throughout the exercise. This SSLS consisted of alternating movements towards knee extension and ankle dorsiflexion (increase of neural tension) combined with cervical extension (decrease of neural tension) on one hand, and knee flexion and ankle plantar flexion (decrease neural tension) combined with cervical flexion (increase of neural tension) on the other. During this 6-week period, each subject in this neurodynamic slider group was instructed to perform 3 sets of 20 repetitions on a daily basis for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static stretch
Description: Subjects in the control group were instructed to perform a standard standing static stretch with the heel of the dominant leg taking support on a chair. Then they had to move the pelvis into anteversion, simultaneously inducing a forward lean of the trunk, until the clear sensation of hamstring stretch was perceived at the posterior aspect of the thigh. Again, the execution of the exercise was thoroughly explained and evaluated by the researchers and subjects sent home with a comprehensive instruction guide and supporting pictures. Each subject was instructed to do 3 repetitions of 30 second static stretches on a daily basis during the 6-week intervention.
Study: NCT01840566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 19-28z T CELLS
Study: NCT01276223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05% ophthalmic emulsion
Description: Topical ocular steroid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Difluprednate vehicle
Description: Inactive ingredients used as Run-In and placebo comparator
Study: NCT02136147

Intervention type: DRUG
Intervention: methylphenidate medication

Intervention type: DRUG
Intervention: methylphenidate medication

Intervention type: DRUG
Intervention: atomoxetine medication

Intervention type: DRUG
Intervention: atomoxetine medication

Intervention type: DRUG
Intervention: lisdexamphetamine medication

Intervention type: DRUG
Intervention: lisdexamphetamine medication

Intervention type: DRUG
Intervention: guanfacine medication

Intervention type: DRUG
Intervention: guanfacine medication
Study: NCT01785823

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FX2-2-2
Description: Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
Study: NCT01858649

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metastases resection
Description: Surgery of colorectal cancer metastases will be proceeded after 3 to 6 cycles of chemotherapy ( folfox or folfiri) + bevacizumab .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metastases resection
Description: Surgery of colorectal cancer metastases will be proceeded after 3 to 6 cycles of chemotherapy ( folfox or folfiri) + bevacizumab .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg in 100 ml NaCl 0.9% IV infusion 3 to 5 cycles. No bevacizumab for ultimate cycle .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg in 100 ml NaCl 0.9% IV infusion 3 to 5 cycles. No bevacizumab for ultimate cycle .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 FU
Description: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, IV infusion 3 to 6 cycles 5-FU bolus 400 mg/m2, IV bolus 3 to 6 cycles 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion 3 to 6 cycles
Study: NCT01840566

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Study: NCT01409642

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Child CBT
Description: 12 sessions of individual child focused cognitive behavior therapy with a parent component

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Family Interaction Therapy
Description: Six sessions of family-focused treatment for childhood OCD administered as an adjunct to 12 sessions of child CBT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Family Interaction Therapy
Description: Positive Family Interaction Therapy (PFIT) is a 6-session treatment designed to be used as an adjunct to standard child CBT in cases where OCD is complicated by challenging family dynamics.
Study: NCT01932528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg [14C]-LX1606
Description: 500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of radiation as \[14C\]-LX1606.
Study: NCT04030351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food - dried fruit
Description: raisins, apricots, figs, and pineapple
Study: NCT04755751

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing (CPET)
Description: CPET using a cycle ergometer (COSMED, Rome, Italy) beginning with a no resistance warm up lasting 1 to 3 minutes and followed with an incrementing resistance adapted to the patient's functional capacities according to the examiner's free judgment and ranging from no resistance (20 Rounds Per Minute (RPM)/minute) 5 to 20 Watts/minute on ramps or by successive stages
Study: NCT01701531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBCPF
Study: NCT03775733

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolysed Red Ginseng Extract
Description: Hydrolysed Red Ginseng Extract 2.4g/day for 12 weeks.
Study: NCT02665104

Intervention type: DEVICE
Intervention: transcranial Doppler (TCD) and INVOS monitor
Description: Bilateral transcranial Doppler measurements of the blood flow velocity within the middle cerebral arteries: 1. before local anesthesia, 2. after the onset of local anesthetic, but before skin incision, 3. intraoperatively before clamping the internal carotid artery, 4. one minute after clamping the internal carotid artery, 5. five minutes after clamping the internal carotid artery, 6. fifteen minutes after clamping the internal carotid artery, 7. directly after the restoration of blood flow in the internal carotid artery, 8. postoperatively, 4-6 hours after the intervention.
Study: NCT03775733

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks.
Study: NCT04143828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile mindfulness programme
Description: The mobile mindfulness programme adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of six modules. Each module consists of a short movie (talking head) explaining the content and two audiofiles to guide experiential mindfulness meditation exercises. Participants can follow the different modules based on their own time-schedule.~Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience.
Study: NCT03657225

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Utilization of the mini CPB circuit
Description: Comparison of the mini CPB circuit to conventional circuit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Utilization of the conventional circuit
Description: Comparison of the mini CPB circuit to conventional circuit
Study: NCT01160328

Intervention type: DRUG
Group type: OTHER
Intervention: Leuprolide
Description: 7.5 mg - 1 month depot, 2 doses over 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: 7.5 mg - 1 month depot, 2 doses over 7 weeks
Study: NCT01785823

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FX2-2-2
Description: Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D6-4-2
Description: Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
Study: NCT01160328

Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone
Description: 7.5g - 1% testosterone gel, daily x 7 weeks
Study: NCT01045668

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Catheter Ablation (RFCA)
Description: RFCA of clinical VT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Catheter Ablation (RFCA)
Description: RFCA of clinical VT as well as VT substrates
Study: NCT03647085

Intervention type: DEVICE
Intervention: Wearable cardiac monitor
Description: Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.
Study: NCT01785823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D6-4-2
Description: Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D8-4-2
Description: Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
Study: NCT01785823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D8-4-2
Description: Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
Study: NCT02702414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion
Study: NCT01950312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab
Study: NCT04137250

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hamstring
Description: The intervention will consist of make an incision on the medial side of the proximal portion of the leg approximately 3 centimeters to dissect by planes until the tendons of the hamstrings are located, which will be removed surgically with specialized instruments and the wound will be closed, for later These tendons be used as an autograft for the reconstruction of the anterior cruciate ligament
Study: NCT03602209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of infected implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Removal of infected implant
Study: NCT00510354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Study: NCT04137250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadriceps tendon
Description: orThe intervention consisted in making an incision in the anterior aspect of the distal portion of the thigh of approximately 3 centimeters to dissect by planes until locating the membranous portion of the quadriceps tendon, from which will be removed a portion of surgical way with specialized instruments and the Wound will be closed, for later this tendon to be used as an autograft for the reconstruction of the anterior cruciate ligament.
Study: NCT03390309

Intervention type: OTHER
Group type: OTHER
Intervention: Partially Hydrolyzed Formula
Description: Partially Hydrolyzed Whey Protein Infant Formula
Study: NCT00559546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: 10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner
Study: NCT03390309

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Formula
Description: Normal Formula
Study: NCT06583746

Intervention type: OTHER
Intervention: Group1
Description: 30 children with DCP were included. The lower extremity evaluations of these cases were made according to ICF. Modified Ashworth Scale (MAS) was used for body structure and functions, Gillette Functional Assessment Questionnaire (FAQ) was used for activity and Pediatric Functional Independence Measure (WeeFIM) was used for participation.
Study: NCT01646242

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: removal of eligible polyps using cold snare polypectomy technique
Description: Snare polypectomy using a mini (10 mm open diameter) size electrosurgical snare without application of electrocautery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: removal of eligible polyps using double biopsy technique
Description: Cold forceps polypectomy using a standard- capacity forceps with double biopsy technique (two bites per one forceps pass)
Study: NCT00383942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol,25 micrograms every 4 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter
Description: A catheter with extra amniotic saline infusion (EASI) is placed in the uterus and applies pressure to the cervix to cause it to ripen
Study: NCT01936415

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard
Description: A prospective randomized study where the patients are randomized to receive one of two prostheses (tibial components) with different coating: Vanguard pourous coating, Biomet and Regenerex® Primary Tibial Tray, Biomet. Both prostheses are available and approved by the FDA. The main difference between the implants is the coating of the tibial tray

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regenerex
Study: NCT00741403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: CPI-613, the investigational drug, is a novel anti-tumor compound believed to operate via a novel mechanism of action that does not belong to any existing pharmacological class of anticancer agents currently being used in the clinics. Specifically, CPI-613 is Cornerstone Pharmaceutical Inc.'s lead drug from its Altered Energy Metabolism-Directed (AEMD) technology platform. It is selective against tumor cells (but not normal cells)according to preclinical studies
Study: NCT01852812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast Oral Granules (OG)
Description: Montelukast 4 mg in one sachet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast Chewable Tablets (CT)
Description: Montelukast 5 mg in one tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast Chewable Tablets (CT)
Description: Montelukast 5 mg in one tablet
Study: NCT02567006

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS message
Description: SMS messages will be delivered at 6, 4, and 2 days before the next scheduled date of the primary vaccines for the intervention group

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Health clinic nurse provides regular appointment in the vaccination card with no active reminders
Study: NCT01684371

Intervention type: OTHER
Intervention: Two oily solutions (Blue Dotted and Orange Dotted Elmore Oils)
Description: Thirty participants received Blue Dotted Elmore Oil and another thirty received the Orange dotted Elmore Oil, they applied the oils three times daily on the affected knees for four weeks and stopped usage on the fifth week (flush out period) and on the 6 week, the two group switched to Orange and Blue Elmore Oil respectively. All throughout applications, they filled out their diaries to indicate changes in their mobility, moods, feeling of well being and ability to do their daily work at home or at work every week.

Intervention type: OTHER
Intervention: Two oily solutions (Blue Dotted and Orange Dotted Elmore Oils)
Description: Thirty participants received Blue Dotted Elmore Oil and another thirty received the Orange dotted Elmore Oil, they applied the oils three times daily on the affected knees for four weeks and stopped usage on the fifth week (flush out period) and on the 6 week, the two group switched to Orange and Blue Elmore Oil respectively. All throughout applications, they filled out their diaries to indicate changes in their mobility, moods, feeling of well being and ability to do their daily work at home or at work every week.
Study: NCT01425554

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Doppler sonography of internal jugular veins
Description: Doppler sonography of internal jugular veins

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Magnetic resonance venography of internal jugular veins
Description: Magnetic resonance venography of internal jugular veins

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Air-plethysmography of the neck
Description: Air-plethysmography of the neck

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Catheter venography of internal jugular veins
Description: Catheter venography of internal jugular veins
Study: NCT02596269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: 120 mg of nefopam is included in the i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time was set, without any background continuous infusion. After the end of surgery, and if the goal VRS score was achieved at PACU, PCA device was turned on and the patient was encouraged to use the pre-set bolus dose, until 24h after the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time
Study: NCT03602209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic durations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic durations
Study: NCT00556309

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
Study: NCT03136809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu(II)ATSM
Description: copper-containing synthetic small molecule